JMP Says Stepping To The Sidelines On Achillion

Loading...
Loading...
In a report published Wednesday, JMP Securities analysts downgraded the rating on
Achillion Pharmaceuticals, Inc.ACHN
from Market Outperform to Market Perform. The analysts prefer to stay in the sidelines while the company reinvents itself by outsourcing HCV and focuses on its preclinical assets. "[W]hile the Factor D platform appears to have blockbuster potential, in our view, it remains early in development," the analysts said, while adding, ACHN announced that it has signed a worldwide collaboration with
Johnson & JohnsonJNJ
in return for: 1) a mid-teens to lowtwenties royalty on future HCV sales; 2) $875M in future milestones; and 3) a $225M equity investment." Under this partnership, Johnson & Johnson will take on the responsibilities of R&D and commercialization, while Achillion provides the HCV assets. "Our thesis for owning ACHN had been based on an outright acquisition, following data from its own HCV assets, for which it had one of each class. Given this deal, our thesis no longer holds and we now view ACHN as a company with the potential for a stream of payments from HCV, which it will reinvest into its interesting, but early stage, pipeline of Factor D compounds targeted at various rare diseases," the JMP Securities report stated. The analysts believe that the stock is fairly valued at its current levels.
Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorDowngradesAnalyst RatingsJMP Securities
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...